Dirk Eick

Title: Dirk Eick: Innovator in Monoclonal Antibody Production

Introduction

Dirk Eick is a notable inventor based in Germering, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of human monoclonal antibodies. His innovative work has implications for various medical applications, including diagnostics and therapeutics.

Latest Patents

Dirk Eick holds a patent titled "Process for the preparation of human monoclonal antibodies and their use." This invention provides a process for the preparation of human monoclonal antibodies from human B cells. According to this process, human antibody-producing B cells are immortalized by infection with an Epstein-Barr virus, or a derivative thereof, that expresses Epstein-Barr virus nuclear antigen 2 (EBNA2). The EBNA2 function, which is required for immortalization, is subsequently shut off, resulting in an increase in antibody production. The invention offers a variety of systems that allow expression of EBNA2 function to achieve immortalization, followed by a reduction of EBNA2 expression or function to facilitate antibody production. Dirk Eick has 1 patent to his name.

Career Highlights

Dirk Eick is associated with the GSF-Forschungszentrum für Umwelt und Gesundheit, GmbH, where he conducts his research and development activities. His work focuses on advancing the understanding and application of monoclonal antibodies in various fields.

Collaborations

Dirk Eick has collaborated with notable colleagues, including Georg W Bornkamm and Bettina Kempkes. These collaborations have contributed to the advancement of research in the field of monoclonal antibodies.

Conclusion

Dirk Eick's innovative contributions to the preparation of human monoclonal antibodies highlight his importance in the field of biotechnology. His work not only advances scientific knowledge but also has the potential to impact medical treatments significantly.